Key Takeaways
- • Digital health venture funding reached $7.4 billion in H1 2026, representing a $1 billion increase from the same period in 2025 ($6.4 billion), signaling market recovery and institutional investor confidence in the sector.
- • Mega-deals of $100 million or more dominated capital allocation, with just 19 mega-rounds capturing approximately 60% of all capital raised, reflecting investor preference for companies operating at scale with established health system contracts and patient volumes.
- • AI agent platforms emerged as the primary funding category, exemplified by Assort Health's $120 million Series C round (led by Menlo Ventures with participation from Lightspeed, Felicis, and First Round Capital), which valued the company at $1.2 billion and highlighted the competitive advantage of training data at scale—Assort's platform processes over 190 million patient interactions annually.
- • Capital concentration across four strategic categories—AI scheduling agents, chronic disease monitoring, home health operations, and healthcare workforce training—indicates institutional investors are betting on operational efficiency and labor augmentation rather than early-stage diagnostic or consumer wellness solutions.
- • Average deal size climbed to $29.6 million, up 46% year-over-year, underscoring a market bifurcation where well-capitalized, operationally mature platforms command disproportionate investor attention while early-stage ventures face continued funding pressure.
Summary
Digital health venture capital rebounded sharply in the first half of 2026, reaching $7.4 billion in total funding—a $1 billion increase compared to the same period in 2025. This rebound reflects a maturing market where capital concentration in mega-deals signals a fundamental shift in investor strategy: institutional money is flowing predominantly toward platforms already operating at scale with proven health system relationships and substantial patient data sets, rather than prototype-stage companies or point solutions.
The funding surge was driven by mega-deals exceeding $100 million, which accounted for nearly half of all capital deployed. This concentration dynamic was particularly evident in June 2026, when four major funding rounds totaling $335 million closed across complementary healthcare technology categories. The largest disclosed transaction was Assort Health's $120 million Series C round, led by Menlo Ventures with participation from Lightspeed Venture Partners, Felicis Ventures, and First Round Capital. The round valued Assort at $1.2 billion—representing $222 million in total capital raised to date—and underscored a critical competitive threshold: the company's AI agent platform operates on over 190 million historical patient interactions, enabling sophisticated automation across scheduling, intake, referrals, document processing, medication refills, and payment workflows. This data volume provides a meaningful moat against competitors still learning basic operational workflows.
Capital deployment concentrated across four strategic technology categories: AI scheduling and workflow agents, chronic disease monitoring platforms, home health operations tools, and healthcare workforce training solutions. This allocation reflects investor conviction that operational efficiency and labor augmentation represent the highest-return applications of venture capital in healthcare, as opposed to diagnostic innovation or direct-to-consumer wellness products. Each funded company demonstrated institutional-grade credentials upon closing: established contracts with major health systems, active patient volumes, and valuation benchmarks that signal confidence among tier-one institutional investors.
The metrics underlying this funding environment further illuminate market dynamics: average deal size reached $29.6 million, a 46% year-over-year increase, while just 19 mega-rounds captured approximately 60% of all capital raised in H1 2026. This bifurcation indicates a challenging environment for early-stage digital health ventures competing outside the mega-round cohort, even as the broader sector demonstrates sustained institutional appetite for companies demonstrating operational maturity and defensible competitive positions grounded in proprietary data or network effects.
The funding surge was driven by mega-deals exceeding $100 million, which accounted for nearly half of all capital deployed. This concentration dynamic was particularly evident in June 2026, when four major funding rounds totaling $335 million closed across complementary healthcare technology categories. The largest disclosed transaction was Assort Health's $120 million Series C round, led by Menlo Ventures with participation from Lightspeed Venture Partners, Felicis Ventures, and First Round Capital. The round valued Assort at $1.2 billion—representing $222 million in total capital raised to date—and underscored a critical competitive threshold: the company's AI agent platform operates on over 190 million historical patient interactions, enabling sophisticated automation across scheduling, intake, referrals, document processing, medication refills, and payment workflows. This data volume provides a meaningful moat against competitors still learning basic operational workflows.
Capital deployment concentrated across four strategic technology categories: AI scheduling and workflow agents, chronic disease monitoring platforms, home health operations tools, and healthcare workforce training solutions. This allocation reflects investor conviction that operational efficiency and labor augmentation represent the highest-return applications of venture capital in healthcare, as opposed to diagnostic innovation or direct-to-consumer wellness products. Each funded company demonstrated institutional-grade credentials upon closing: established contracts with major health systems, active patient volumes, and valuation benchmarks that signal confidence among tier-one institutional investors.
The metrics underlying this funding environment further illuminate market dynamics: average deal size reached $29.6 million, a 46% year-over-year increase, while just 19 mega-rounds captured approximately 60% of all capital raised in H1 2026. This bifurcation indicates a challenging environment for early-stage digital health ventures competing outside the mega-round cohort, even as the broader sector demonstrates sustained institutional appetite for companies demonstrating operational maturity and defensible competitive positions grounded in proprietary data or network effects.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.